Exhibit 4.1

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE OFFERED, SOLD, OR OTHERWISE TRANSFERRED UNLESS THEY ARE REGISTERED UNDER THE ACT AND ALL APPLICABLE STATE SECURITIES LAWS OR ARE IN COMPLIANCE WITH AN EXEMPTION THEREFROM.

CONVERTIBLE PROMISSORY NOTE

FOR VALUE RECEIVED, VIVOS THERAPEUTICS, INC., a Delaware corporation (the “Company”), hereby promises to pay to V-CO INVESTORS 4 LLC, a Wyoming limited liability company, or permitted assigns (the “Lender”) the maximum base principal sum of up to Five Million Dollars ($5,000,000) (the “Maximum Principal Amount”) together with accrued and unpaid interest (“Interest”) on the Principal amount actually funded, on demand in accordance with the terms of this Convertible Promissory Note (this “Note”). Interest shall only begin to accrue upon the occurrence of an Event of Default at a simple interest rate equal to fifteen percent (15%) per annum. Interest shall be computed on the basis of a 365-day year (or 366-day year, as appropriate) applied to actual days elapsed.

1. Purpose. The purpose of this Note is to provide short-term advanced funding to the Company in connection with a proposed equity financing of the Company totaling up to $5,500,000 (currently anticipated, but not for purposes of the Note required, to be sponsored by the Lender or its affiliates, the “Financing”) that is expected to be completed no later than June 30, 2026 (the “Outside Date”). At any given time through close of business on the Outside Date, Lender shall advance funds and confirm such amount in advance to the Company up to the Maximum Principal Amount. It being agreed that $500,000 of the Maximum Principal Amount shall be advanced on the Date of Issuance. Notwithstanding the foregoing, the Lender will offset all unreimbursed accumulated out of pocket expenses incurred to date by Seneca Partners related to its activities with Vivos (and will provide Vivos with a schedule supporting such expenses).

At any given time, the “Principal” shall reflect the amount funded by Lender to the Company as of the date thereof plus a bridge financing fee (which shall be treated as an original issuance discount) of ten percent (10%) of the amount funded, as shown on Schedule A hereto. Schedule A shall be amended from time to time through the Outside Date as the Lender advances additional funds.

By its acceptance of this Note, the Lender, on behalf of itself and its affiliates V-CO Investors LLC, V-Co Investors 2 LLC, V-Co Investors 3 LLC (“V-Co 3”), SP Manager LLC and Michael C. Skaff, acknowledges and agrees that (i) this Note is separate and distinct and represents a different funding from that certain Convertible Promissory Note, dated January 15, 2026, made by the Company in favor of V-Co 3 (the “Prior Note”) and (ii) the Prior Note was terminated and converted into equity securities of the Company on March 31, 2026.

2. Due on Demand. The Company shall pay to the order of the Lender the unpaid Principal, together with all Interest, immediately ON DEMAND given by the Lender to the Company. The Lender may not demand payment prior to the Outside Date.

3. Payment. All payments shall be made in cash in lawful money of the United States of America at the principal office of Lender at 18000 Mack, Grosse Pointe, MI 48230, or at such other place as the holder hereof may from time to time designate in writing to the Company or by wire transfer of immediately available funds to an account designated in writing by the Lender. Payment shall be credited first to accrued and unpaid Interest (if any) and second to Principal. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. The Company’s obligations hereunder are absolute and unconditional and shall not be subject to setoff, recoupment or counterclaim. Following the Outside Date, all Principal and any accrued Interest may be prepaid in whole or in part without penalty.

4. Events of Default. The occurrence of any of the following shall constitute an “Event of Default” under this Note:

(a) Failure to Pay. The Company shall fail to pay, when due, any Interest payment, Principal payment or other payment required under the terms of this Note on demand and such payment shall not have been made within three (3) business days of the Company’s being given notice of such failure to pay; or

(b) Breaches of Covenants. The Company shall fail to observe or perform any other covenant, obligation, condition or agreement contained in this Note (other than those specified in Section 4(b) of this Note) in any material respect, and such failure shall continue for five (5) business days after the Company’s being given notice of such failure; or

(c) Voluntary Bankruptcy or Insolvency Proceedings. The Company shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property, (ii) make a general assignment for the benefit of its or any of its creditors, (iii) be dissolved or liquidated, (iv) commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official in an involuntary case or other proceeding commenced against it or (v) take any action for the purpose of effecting any of the foregoing; or

(e) Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company, or of all or a substantial part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with respect to the Company or any of its subsidiaries, if any, or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding shall not be dismissed or discharged within thirty (30) days of commencement.

5. Rights of Lender upon Default. Upon the occurrence of any Event of Default:

(a) Described in Sections 4(d) or 4(e) and at any time thereafter during the continuance of such Event of Default, immediately and without notice, all outstanding obligations payable by the Company hereunder shall automatically become immediately due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived.

(b) Described in Sections 4(a), 4(b), or 4(c) and at any time thereafter during the continuance of such Event of Default, Lender may, by written notice to the Company, declare all outstanding obligations payable by the Company hereunder to be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived.

In addition to the foregoing remedies in this Section 5, upon the occurrence and during the continuance of any Event of Default, Lender may exercise any other right, power or remedy otherwise permitted to it by law, either by suit in equity or by action at law, or both.

6. Intentionally Omitted.

7. Use of Proceeds. The proceeds of the loan from Lender evidenced by this Note shall be used solely for general working capital purposes.

8. Automatic Conversion of the Note Upon Completion of Financing.

(a) Automatic Conversion. If the Financing is completed prior to the Outside Date, this Note shall automatically and without any further action of the Lender or the Company necessary be exchanged on a dollar-for-dollar basis based on the Principal then outstanding for the equity instruments issued in connection with the Financing (the “Conversion”).

(b) Mechanics and Effect of Conversion. Upon Conversion of this Note, Lender shall surrender this Note (or a notice to the effect that the original Note has been lost, stolen or destroyed and a customary affidavit as to such loss, stealing or destruction); provided, however, that upon such Conversion, this Note shall be deemed exchanged and converted and of no further force and effect, whether or not it is delivered for cancellation as set forth in this sentence, and the Company will be forever released from all of its obligations and liabilities under this Note for payment of any Principal or accrued Interest.

9. Amendments and Waivers. The amendment of any term of this Note shall only be effective if made in a writing signed by the Company and Lender. The Company agrees that any delay on the part of Lender in exercising any rights hereunder will not operate as a waiver of such rights. Lender shall not by any act, delay, omission or otherwise be deemed to have waived any of its rights or remedies, and no waiver of any kind shall be valid unless in writing and signed by the party or parties waiving such rights or remedies.

10. Successors and Assigns. This Note applies to, inures to the benefit of, and binds the successors and assigns of the parties hereto; provided, however, that neither the Company nor the Lender may assign or transfer this Note or any of its obligations hereunder without the prior written consent of the other party.

11. Usury. If it shall be found that any Interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate of Interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it will not seek to claim or take advantage of any law that would prohibit or forgive the Company from paying all or a portion of the Principal or Interest on this Note.

12. Expenses. Lender shall be entitled to recover from the Company all fees, costs and expenses, including legal expenses, of preparing this Note (up to a maximum of $10,000 in the aggregate) and enforcing any provision under or with respect to this Note, or collecting any amount due thereunder, including, without limitation, reasonable fees and expenses of attorneys, which shall include, without limitation, all fees, costs and expenses of appeals.

13. Governing Law; Jurisdiction. This Note will be governed by, construed in accordance with and interpreted under and consistent with the laws and decisions of the State of Delaware, without regard to the choice of law provisions thereof. The parties irrevocably agree, and hereby consent and submit to the exclusive jurisdiction of the state and federal courts in the City of Denver, Colorado, with regard to any actions or proceedings arising from, relating to or in connection with the enforcement and/or interpretation of the provisions of this Note and the transactions contemplated herein.

14. Electronic Copy. Any electronic copy of this Note shall be fully enforceable to the same extent as an originally executed version physically delivered in person; provided, that all copies hereof shall constitute one and the same instrument. Any electronic execution or delivery of this Note shall be fully effective to the same extent as the physical execution and in-person delivery of this Note. The Company hereby waives any defense or claim to the contrary. If this Note is executed or delivered electronically, the Company shall, upon Lender’s request, physically deliver to Lender an originally executed version of this Note. If no original of this Note has been delivered to Lender, any requirement to surrender or return of this Note may be satisfied by the electronic delivery of an electronic copy of this Note.

15. Severability. If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability shall not affect any other term or provision of this Note or invalidate or render unenforceable such term or provision in any other jurisdiction.

16. Entire Agreement. This Note represents the complete and integrated agreement of the Company and the Lender with respect to the matters contemplated hereby, superseding and replacing in all respects any prior discussions, promises, covenants or agreements of the Company and the Lender with respect to such subject matter.

[Signature Page Follows]

This Convertible Promissory Note has been executed as of the date first written above.

Schedule A

Principal

Exhibit 10.1

THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED.

Exchange Agreement

This Exchange Agreement (this “Agreement”) is executed as of June 5, 2026 by and between Vivos Therapeutics, Inc., a Delaware corporation (“Borrower”), and Streeterville Capital, LLC, a Utah limited liability company (“Lender”). Capitalized terms not defined herein shall have the same meaning as set forth in the Transaction Documents (as defined below).

A. Pursuant to that certain Note Purchase Agreement dated June 9, 2025 (“Purchase Agreement”) between Lender and Borrower, Borrower issued to Lender that certain Secured Promissory Note in the original principal amount of $8,225,000.00 and having an original issue date of June 9, 2025 (“Original Note,” and together with the Purchase Agreement and all other agreements and documents entered into in conjunction therewith, the “Transaction Documents).

B. Subject to the completion of the First Tranche Financing (as defined below) by the Outside Date (as defined below), Borrower and Lender desire to partition $3,250,000.00 of the Original Note (as may be increased in accordance with the terms hereof, the “Partitioned Amount”) from the Original Note (the “Partitioned Note”) and then cause the outstanding balance of the Original Note to be reduced by an amount equal to the Partitioned Amount.

C. Borrower and Lender further desire to exchange (such exchange is referred to as the “Exchange”) the Partitioned Note for (i) 2,500 shares of newly designated Series A Preferred Stock, par value $0.0001, of Borrower (the “Exchange Preferred Shares”), the terms of which are set forth in the Certificate of Designation for such Exchange Preferred Shares, in the form attached hereto as Exhibit A (the “Certificate of Designation”), and (ii) a number of shares (the “Exchange Common Shares”, and together with the Exchange Preferred Shares, the “Exchange Shares”) of common stock, par value $0.0001 per share (the “Common Shares”), equal to $750,000.00 divided by the Nasdaq Minimum Price on the Closing Date (as defined below), all according to the terms and conditions of this Agreement.

D. This Agreement, the Certificate of Designation, the Original Note Amendment (as defined below), and any other documents, agreements, or instruments entered into or delivered in connection with this Agreement, or any amendments to any of the foregoing, are collectively referred to as the “Exchange Documents”.

E. Pursuant to the terms and conditions hereof, Lender and Borrower agree to exchange the Partitioned Note for the Exchange Shares and to allow for (i) an increase in the Partitioned Amount, (ii) the creation of a second Partitioned Note and (iii) a second exchange transaction, all as provided for herein.

NOW, THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties and covenants herein contained, the parties hereto agree as follows:

1. Recitals and Definitions. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this Agreement are true and accurate, are contractual in nature, and are hereby incorporated into and made a part of this Agreement.

2. Partition; Original Note Amendment.

(a) Upon completion of the First Tranche Financing on or before the Outside Date, Borrower and Lender agree that the Partitioned Amount will automatically be partitioned from the Original Note.

(b) An additional portion of the Original Note will be automatically partitioned into a second Partitioned Note (the “Second Partitioned Note”) upon the occurrence of the Second Tranche Financing (as defined below) on or before the Outside Date.

(c) Following any such partition of the Original Note, Borrower and Lender agree that the Original Note shall remain in full force and effect, provided that: (i) the outstanding balance of the Original Note shall automatically be reduced by an amount equal to the Partitioned Amount, subject to further reduction as contemplated by Section 3(b), and (ii) the Original Note shall automatically be amended by those amendments set forth in that certain Note Amendment attached hereto as Exhibit B (the “Original Note Amendment”).

3. Issuance of Exchange Shares.

(a) Immediately and automatically upon Borrower completing a common stock financing pursuant to which it receives gross proceeds of at least $2,600,000 (the “First Tranche Financing”), provided that the First Tranche Financing is completed on or prior to June 15, 2026 (the “Outside Date”), and pursuant to the terms and conditions of this Agreement, the Exchange will occur with Lender surrendering the Partitioned Note to Borrower and Borrower issuing to Lender the Exchange Shares. In conjunction therewith, Borrower hereby confirms that the Partitioned Note represents Borrower’s unconditional obligation to pay the outstanding balance thereof pursuant to the terms of the Partitioned Note. Borrower and Lender agree that upon surrender, and provided that Lender has received the Exchange Common Shares free and clear of any restrictive legends, the Partitioned Note will be cancelled and all obligations of Borrower under the Partitioned Note shall be deemed fulfilled. In the event the First Tranche Financing does not occur by the Outside Date, this Agreement will immediately and automatically terminate and be deemed void ab initio.

(b) Immediately and automatically upon Borrower completing a common stock financing pursuant to which it receives additional gross proceeds of at least $1,900,000.00, separate and apart from, and in addition to, the $2,600,000 of gross proceeds received in the First Tranche Financing (the “Second Tranche Financing”), provided that the Second Tranche Financing occurs on or prior to the Outside Date, and pursuant to the terms and conditions of this Agreement, a second exchange will occur (the “Second Exchange”), with Lender surrendering the Second Partitioned Note (in the principal amount of $1,250,000) in exchange for Borrower issuing to Lender an additional 1,250 Exchange Preferred Shares. In conjunction therewith, Borrower hereby confirms that the Original Note as so reduced would represent Borrower’s unconditional obligation to pay the outstanding balance thereof pursuant to the terms of the Original Note (as amended by the Note Amendment). Borrower and Lender agree that upon surrender, and provided that Lender has received such additional Exchange Preferred Shares, the Second Partitioned Note exchanged will be cancelled and all obligations of Borrower under the Second Partitioned Note shall be deemed fulfilled.

4. Closing Date; Deliveries. The closings of the transactions contemplated hereby (each, a “Closing”), along with the delivery of the applicable Exchange Shares to Lender, shall occur immediately, and without further approvals or action required, as of the closing of the First Tranche Financing on or before the Outside Date or, as applicable, the Second Tranche Financing on or before the Outside Date (collectively, the “Closing Date”), by means of the exchange of electronic signatures, but shall be deemed to have occurred at the offices of Capital Law Partners PLLC in Lehi, Utah. On the Closing Date, prior to or contemporaneously with the execution and delivery of this Agreement, the following events shall occur:

4.1. Borrower shall have issued all applicable Exchange Common Shares or Exchange Preferred Shares, as the case may be, to Lender.

4.2. Mutual execution and delivery of all other Exchange Documents, as applicable, including without limitation this Agreement.

5. Holding Period, Tacking and Legal Opinion. Borrower represents, warrants and agrees that for the purposes of Rule 144 (“Rule 144”) of the Securities Act of 1933, as amended (the “Securities Act”), the holding period of the Partitioned Note and the Exchange Shares will include the holding period of the Original Note from June 9, 2025, which date is the date that Original Note was fully paid for. Borrower agrees not to take a position contrary to this Section 5 in any document, statement, setting, or situation and further acknowledges that the Partitioned Note has not been amended or altered since its issuance. Borrower agrees to take all action necessary to issue the Exchange Shares without restriction within three (3) business days of the Closing Date, and not containing any restrictive legend without the need for any action by Lender. The Exchange Shares are being issued in substitution of and exchange for and not in satisfaction of the Partitioned Note. The Exchange Shares shall not constitute a novation or satisfaction and accord of the Partitioned Note. Borrower acknowledges and understands that the representations and agreements of Borrower in this Section 5 are a material inducement to Lender’s decision to consummate the transactions contemplated herein.

6. Lender’s Representations, Warranties and Agreements. In order to induce Borrower to enter into this Agreement, Lender, for itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a) Lender has full power and authority to enter into this Agreement and to incur and perform all obligations and covenants contained herein, all of which have been duly authorized by all proper and necessary action, (b) no consent, approval, filing or registration with or notice to any governmental authority is required as a condition to the validity of this Agreement or the performance of any of the obligations of Lender hereunder, (c) no commission or other remuneration has been paid or given directly or indirectly by Lender to Borrower for soliciting the Exchange, and (d) Lender has taken no action which would give rise to any claim by any person for a brokerage commission, placement agent or finder’s fee or other similar payment by Borrower related to this Agreement.

7. Borrower’s Representations, Warranties and Agreements. In order to induce Lender to enter into this Agreement, Borrower, for itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows: (a) Borrower has full power and authority to enter into this Agreement and to incur and perform all obligations and covenants contained herein, all of which have been duly authorized by all proper and necessary action, (b) no consent, approval, filing or registration with or notice to any governmental authority is required as a condition to the validity of this Agreement or the performance of any of the obligations of Borrower hereunder, other than (i) the filing of the Certificate of Designation with the Secretary of State of the State of Delaware and (ii) any securities or stock exchange filings required to be made in connection with the issuance of the Exchange Shares, (c) to the knowledge of Borrower, no Event of Default has occurred under the Original Note, provided that any Events of Default that may have occurred thereunder have not been, and are not hereby, waived by Lender, (d) except as specifically set forth herein, nothing herein shall in any manner release, lessen, modify or otherwise affect Borrower’s obligations under the Original Note, (e) the issuance of the Exchange Shares is duly authorized by all necessary corporate action and the Exchange Shares are validly issued, fully paid and non-assessable, free and clear of all taxes, liens, claims, pledges, mortgages, restrictions, obligations, security interests and encumbrances of any kind, nature and description, (f) Borrower has not received any consideration in any form whatsoever for entering into this Agreement, other than the surrender of the Partitioned Note, and (g) Borrower has taken no action which would give rise to any claim by any person for a brokerage commission, placement agent or finder’s fee or other similar payment by Borrower related to this Agreement.

8. Application of Covenants from Purchase Agreement. Borrower acknowledges and agrees that the covenants contained in Section 4 of the Purchase Agreement will continue to apply in all respects to Borrower and to the Original Note until the Original Note has been repaid in full.

9. Lock-Up Restriction. Subject to completion of the First Tranche Financing on or before the Outside Date, Lender hereby agrees that, without the prior written consent of Borrower, it will not, and its “affiliates” (as defined in Rule 144) will not, during the period commencing on the Closing Date of the First Tranche Financing and ending August 15, 2026 (i) offer, pledge, sell, contract to sell, grant any option or contract to purchase, a purchase option or contract, or otherwise dispose of, directly or indirectly, any Exchange Shares or other Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Exchange Shares or other Common Shares. The Company may impose stop-transfer instructions with respect to the securities subject to this restriction until the end of said period.

10. Maximum Percentage. Any Exchange Common Shares that would cause Lender to exceed the Maximum Percentage shall be held in abeyance and shall not be issued until such time, if ever, as the Lender’s right to receive such shares would not result in a violation of the Maximum Percentage. For purposes of this Section 10, “Maximum Percentage” means 9.99% of the number of shares of Common Shares outstanding on such date (including for such purpose the shares of Common Shares issuable upon such issuance). For purposes of calculating the Maximum Percentage, beneficial ownership of Common Shares will be determined pursuant to Section 13(d) of the 1934 Act.

11. Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of Utah. The provisions set forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference. BORROWER HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

12. Arbitration of Claims. This Agreement shall be subject to the Arbitration Provisions (as defined in the Purchase Agreement) attached as an exhibit to the Purchase Agreement.

13. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic signature (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

14. Attorneys’ Fees. In the event of any arbitration or action at law or in equity to enforce or interpret the terms of this Agreement, the parties agree that the prevailing party shall be entitled to an additional award of the full amount of the attorneys’ fees and expenses paid by such prevailing party in connection with the arbitration, litigation and/or dispute without reduction or apportionment based upon the individual claims or defenses giving rise to the fees and expenses. The “prevailing party” shall be the party in whose favor a judgment is entered, regardless of whether judgment is entered on all claims asserted by such party and regardless of the amount of the judgment; or where, due to the assertion of counterclaims, judgments are entered in favor of and against both parties, then the arbitrator shall determine the “prevailing party” by taking into account the relative dollar amounts of the judgments or, if the judgments involve nonmonetary relief, the relative importance and value of such relief. Nothing herein shall restrict or impair an arbitrator’s or a court’s power to award reasonable fees and expenses for frivolous or bad faith pleading.

15. No Reliance. Borrower acknowledges and agrees that neither Lender nor any of its officers, directors, members, managers, equity holders, representatives or agents has made any representations or warranties to Borrower or any of its agents, representatives, officers, directors, or employees except as expressly set forth in this Agreement, the Transaction Documents, and the Exchange Documents, and, in making its decision to enter into the transactions contemplated by this Agreement, Borrower is not relying on any representation, warranty, covenant or promise of Lender or its officers, directors, members, managers, equity holders, agents or representatives other than as set forth in this Agreement.

16. Severability. If any part of this Agreement is construed to be in violation of any law, such part shall be modified to achieve the objective of the parties to the fullest extent permitted and the balance of this Agreement shall remain in full force and effect.

17. Entire Agreement. This Agreement, together with the Exchange Documents, and all other documents referred to herein, supersedes all other prior oral or written agreements among Borrower, Lender, its affiliates and persons acting on its behalf with respect to the matters discussed herein, and this Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither Lender nor Borrower makes any representation, warranty, covenant or undertaking with respect to such matters.

18. Amendments. This Agreement may be amended, modified, or supplemented only by written agreement of the parties. No provision of this Agreement may be waived except in writing signed by the party against whom such waiver is sought to be enforced.

19. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Lender hereunder may be assigned by Lender to a third party in whole or in part. Borrower may not assign this Agreement or any of its obligations herein without the prior written consent of Lender.

20. Continuing Enforceability; Conflict Between Documents. Except as otherwise modified by this Agreement or the Original Note Amendment, the Original Note and each of the other Transaction Documents shall remain in full force and effect, enforceable in accordance with all of its original terms and provisions. This Agreement shall not be effective or binding unless and until it is fully executed and delivered by Lender and Borrower. If there is any conflict between the terms of this Agreement, on the one hand, and the Original Note or any other Transaction Document, on the other hand, the terms of this Agreement shall prevail.

21. Time of Essence. Time is of the essence with respect to each and every provision of this Agreement.

22. Notices. Unless otherwise specifically provided for herein, all notices, demands or requests required or permitted under this Agreement to be given to Borrower or Lender shall be given as set forth in the “Notices” section of the Purchase Agreement.

23. Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

[Remainder of the page intentionally left blank; signature page to follow]

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set forth above.

ATTACHMENTS:

Exhibit A Certificate of Designation

Exhibit B Original Note Amendment

[Signature Page to Exchange Agreement]

Exhibit A

CERTIFICATE OF DESIGNATION OF PREFERENCES AND RIGHTS OF

SERIES A PREFERRED STOCK

of

Vivos Therapeutics, Inc.

a Delaware corporation

Pursuant to Section 151 of the Delaware General Corporation Law

The undersigned, R. Kirk Huntsman, hereby certifies that:

IN WITNESS WHEREOF, the undersigned does hereby execute this Certificate, and does hereby acknowledge that this instrument constitutes his act and deed and that the facts stated herein are true.

Vivos Therapeutics, Inc.

CERTIFICATE OF DESIGNATION OF PREFERENCES AND RIGHTS OF

SERIES A PREFERRED STOCK

of

Vivos Therapeutics, Inc.

a Delaware corporation

The undersigned Chief Executive Officer of Vivos Therapeutics, Inc. (“Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify that, pursuant to the authority contained in the Corporation’s Certificate of Incorporation (“Certificate”) and pursuant to Section 151 of the Delaware General Corporation Law, and in accordance with the provisions of the resolution creating a series of the class of the Corporation’s authorized preferred stock designated as the Series A Preferred Stock as follows:

FIRST: The Certificate, as amended, authorizes the issuance by the Corporation of 200,000,000 shares of common stock, par value of $0.0001 per share (“Common Stock”) and 50,000,000 shares of preferred stock, par value of $0.0001 per share (“Preferred Stock”), and further, authorizes the Board of Directors of the Corporation (“Board”), by resolution or resolutions, at any time and from time to time, to divide and establish any or all of the unissued shares of Preferred Stock not then allocated to any series into one or more series and to designate the rights, preferences and limitations of each series.

SECOND: By unanimous written consent of the Board, dated June 4, 2026, the Board designated ten thousand (10,000) shares of the Preferred Stock as Series A Preferred Stock, par value $0.0001 per share, pursuant to a resolution providing that a series of preferred stock of the Corporation be and hereby is created and that the designation and number of shares thereof and the voting and other powers, preferences and relative, participating, optional or other rights of the shares of such Series A Preferred Stock, and the qualifications, limitations and restrictions thereof, are as follows:

SERIES A PREFERRED STOCK

Section 1. Definitions. Capitalized terms used but not otherwise defined herein shall have meanings set forth in Section 13 below.

Section 2. Powers and Rights of Series A Preferred Stock. There is hereby designated a class of Preferred Stock of the Corporation as Series A Preferred Stock, par value $0.0001 per share, of the Corporation (the “Series A Stock”). The number of shares, powers, terms, conditions, designations, preferences and privileges, relative, participating, optional and other special rights, and qualifications, limitations and restrictions of the Series A Stock shall be as set forth in this Certificate of Designation of Preferences and Rights of Series A Stock (this “Certificate of Designation”). For purposes hereof, a holder of a share or shares of Series A Stock, with respect to their rights as related to the Series A Stock, shall be referred to as a “Series A Holder.”

Section 3. Number and Stated Value. The number of authorized shares of the Series A Stock is ten thousand (10,000) shares. Each share of Series A Stock shall have a stated value of $1,050.00 (the “Stated Value”).

Section 4. Ranking. Except to the extent that the holders of at least a majority of the outstanding Series A Stock (the “Required Holders”) expressly consent to the creation of Parity Stock (as defined below) or Senior Preferred Stock (as defined below), all shares of capital stock of the Corporation shall be junior in rank to all Series A Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (such junior stock is referred to herein collectively as “Junior Stock”). The rights of all such shares of capital stock of the Corporation shall be qualified by the rights, powers, preferences and privileges of the Series A Stock. Without limiting any other provision of this Certificate of Designation, without the prior written consent of the Required Holders, voting separately as a single class, the Corporation shall not hereafter authorize or issue any additional or other shares of capital stock that is (i) of senior rank to the Series A Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the “Senior Preferred Stock”), or (ii) of pari passu rank to the Series A Stock in respect of the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of the Corporation (collectively, the “Parity Stock”). In the event of the merger or consolidation of the Corporation with or into another corporation wherein the Corporation is the surviving entity, the shares of Series A Stock shall maintain their relative rights, powers, designations, privileges and preferences provided for herein and no such merger or consolidation shall provide for a result inconsistent therewith, subject to the other terms and conditions herein.

Section 5. Preferred Return.

Section 6. Liquidation, Dissolution or Winding Up. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, each share of Series A Stock shall be entitled to be paid out of the assets of the Corporation available for distribution to its stockholders, before any payment shall be made to the holders of common stock, $0.0001 par value per share, of the Corporation (the “Common Stock”) by reason of their ownership thereof, an amount per share of Series A Stock equal to the Stated Value at such time plus any accrued but unpaid Preferred Return (as applicable, the “Series A Preferred Liquidation Amount”). If upon any such liquidation, dissolution or winding up of the Corporation, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the Series A Preferred Liquidation Amount, the Series A Holders with respect to their shares of Series A Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. Following the payment of the Series A Preferred Liquidation Amount, if there are any remaining assets of the Corporation available for distribution to its stockholders, the Series A Stock shall not participate in such distributions.

Section 7. No Conversions. The Series A Stock shall not be convertible into shares of Common Stock or into any other class or series of stock of the Corporation.

Section 8. Corporation Optional Redemption.

Section 9. Dividends and Distributions. The Series A Stock shall not participate in any dividends, distributions or payments to the holders of the Common Stock.

Section 10. Vote; Amendment.

Section 11. Covenants. Until such time as no shares of Series A Stock remain outstanding, the Corporation and any subsidiary (to the extent applicable) will at all times comply with the following covenants:

Section 12. Covenant Default.

Section 13. Definitions. In addition to the terms defined elsewhere in this Certificate of Designation, the following terms, as used herein, have the following meanings:

Section 14. Miscellaneous.

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, NOR REGISTERED NOR QUALIFIED UNDER ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, OR HYPOTHECATED UNLESS QUALIFIED AND REGISTERED UNDER APPLICABLE STATE AND FEDERAL SECURITIES LAWS OR UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY, SUCH QUALIFICATION AND REGISTRATION IS NOT REQUIRED. ANY TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS FURTHER SUBJECT TO OTHER RESTRICTIONS, TERMS AND CONDITIONS WHICH ARE SET FORTH HEREIN.

[Signature Page Follows]

IN WITNESS WHEREOF, Vivos Therapeutics, Inc., a Delaware corporation, has caused this Certificate of Designation to be signed by a duly authorized officer on June __, 2026.

Exhibit B

AMENDMENT TO SECURED PROMISSORY NOTE

This Amendment to Secured Promissory Note (this “Amendment”) is entered into as of June __, 2026, by and between Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and Vivos Therapeutics, Inc., a Delaware corporation (“Borrower”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Note (as defined below).

A. Borrower previously issued to Lender that certain Secured Promissory Note in the original principal amount of $8,225,000.00 dated June 9, 2025 (the “Note”) pursuant to that the certain Note Purchase Agreement between Borrower and Lender (the “Note Purchase Agreement,” and together with the Note and all documents entered into in connection therewith, the “Transaction Documents”).

B. Lender and Borrower have agreed, subject to the terms, amendments, conditions and understandings expressed in this Amendment, to extend the Maturity Date, reduce the Maximum Monthly Redemption Amount (as defined below), and insert a new “Limited Redemption” section.

C. This Amendment is entered into by and between Borrower and Lender pursuant to that certain Exchange Agreement, dated June __, 2026, between Lender and Borrower (the “Exchange Agreement”).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. Recitals. Each of the parties hereto acknowledges and agrees that the recitals set forth above in this Amendment are true and accurate and are hereby incorporated into and made a part of this Amendment.

2. Conditionality of Amendment. The amendments set forth in this Amendment are expressly conditioned upon Borrower completing a common equity financing where Borrower receives gross proceeds of at least $2,600,000 (the “Financing”) on or before June 15, 2026 (the “Outside Date”). Unless and until the Financing is completed on or before the Outside Date, this Amendment shall be of no force or effect, no amendment, waiver, modification or other change to the Note shall be deemed to have occurred, and the Note shall remain in full force and effect in accordance with its existing terms. Immediately upon consummation of the Financing, this Amendment shall automatically become effective and the Note modified accordingly.

3. Maturity Date. Upon completion of the Financing by the Outside Date, the Maturity Date will automatically be extended to June 10, 2027.

4. Limited Redemptions. Upon completion of the Financing by the Outside Date, Section 4 of the Note will automatically be deleted in its entirety and replaced with the following:

“4. Redemptions.

23.1. Monthly Redemptions. Beginning on December 10, 2025, Lender shall have the right, exercisable at any time in its sole and absolute discretion, to redeem up to the Maximum Monthly Redemption Amount (such amount, the “Redemption Amount”) per calendar month by providing written notice to Borrower (each, a “Redemption Notice”). For the avoidance of doubt, Lender may submit to Borrower one (1) or more Redemption Notices in any given calendar month up to the Maximum Monthly Redemption Amount. Upon receipt of a Redemption Notice, Borrower shall pay the applicable Redemption Amount to Lender in cash within three (3) Trading Days.

23.2. Redemption Standstill. Notwithstanding the foregoing or anything other provision herein or in any related agreement or instrument to the contrary, for the period beginning on the effective date of this Amendment and ending September 15, 2026, Lender shall be prohibited in all instances from engaging in any redemptions of all or any portion of the Maximum Monthly Redemption Amount or the Note generally, but only so long as no Event of Default (as defined in the Note) has occurred under the Note.

23.3. Limited Redemptions. Beginning on December 10, 2025, if at any time thereafter a Limited Redemption Event occurs, Lender shall have the right to submit a Redemption Notice in an amount up to the Maximum Limited Redemption Amount at any time during the applicable Limited Redemption Window (each, a “Limited Redemption”). Borrower must pay the applicable Limited Redemption amount to Lender in cash within three (3) Trading Days of delivery of the applicable Redemption Notice. For the avoidance of doubt, Limited Redemptions will not count toward the Maximum Monthly Redemption Amount.”

5. Additional Definitions. Upon the occurrence of a Financing by the Outside Date, the following definitions shall be added in alphabetical order in Attachment 1 – Definitions, with other definitions in such attachment being renumbered accordingly:

(a) “Limited Redemption Event” means that on any given Trading Day the Common Shares trade at a price that is at least ten percent (10%) greater than the Nasdaq Minimum Price for such Trading Day.

(b) “Limited Redemption Window” means the period beginning on the date a Limited Redemption Event occurs and ending on the date that is five (5) Trading Days after the date the Limited Redemption Event occurs. For the avoidance of doubt, more than one (1) Limited Redemption Window may be open at the same time.

(c) “Maximum Limited Redemption Amount” means ten percent (10%) of the cumulative daily dollar trading volume on the Trading Day that a Limited Redemption Event occurs; measured as the cumulative dollar trading volume on all exchanges beginning at 4:01 PM Eastern Time on the Trading Day before the occurrence of the Limited Redemption Event and ending at 4:00 PM Eastern Time on the Trading Day during which the Limited Redemption Event occurs.

(d) “Maximum Monthly Redemption Amount” means $225,000.00.

(e) “Nasdaq Minimum Price” means the Minimum Price as defined under Nasdaq Rule 5635(d).

6. Representations and Warranties. In order to induce Lender to enter into this Amendment, Borrower, for itself, and for its affiliates, successors and assigns, hereby acknowledges, represents, warrants and agrees as follows:

(a) Borrower has full power and authority to enter into this Amendment and to incur and perform all obligations and covenants contained herein, all of which have been duly authorized by all proper and necessary action. No consent, approval, filing or registration with or notice to any governmental authority is required as a condition to the validity of this Amendment or the performance of any of the obligations of Borrower hereunder.

(b) There is no fact known to Borrower which Borrower has not disclosed to Lender on or prior to the date of this Amendment which would materially and adversely affect the understanding of Lender expressed in this Amendment or any representation, warranty, or recital contained in this Amendment.

(c) Except as expressly set forth in this Amendment, Borrower acknowledges and agrees that neither the execution and delivery of this Amendment nor any of the terms, provisions, covenants, or agreements contained in this Amendment shall in any manner release, impair, lessen, modify, waive, or otherwise affect the liability and obligations of Borrower under the terms of the Transaction Documents.

(d) Borrower has no defenses, affirmative or otherwise, rights of setoff, rights of recoupment, claims, counterclaims, actions or causes of action of any kind or nature whatsoever against Lender, directly or indirectly, arising out of, based upon, or in any manner connected with, the transactions contemplated hereby, whether known or unknown, which occurred, existed, was taken, permitted, or begun prior to the execution of this Amendment and occurred, existed, was taken, permitted or begun in accordance with, pursuant to, or by virtue of any of the terms or conditions of the Transaction Documents. To the extent any such defenses, affirmative or otherwise, rights of setoff, rights of recoupment, claims, counterclaims, actions or causes of action exist or existed, such defenses, rights, claims, counterclaims, actions and causes of action are hereby waived, discharged and released. Borrower hereby acknowledges and agrees that the execution of this Amendment by Lender shall not constitute an acknowledgment of or admission by Lender of the existence of any claims or of liability for any matter or precedent upon which any claim or liability may be asserted.

7. Certain Acknowledgments. Each of the parties acknowledges and agrees that no property or cash consideration of any kind whatsoever has been or shall be given by Lender to Borrower in connection with the amendment to the Note granted herein.

8. Other Terms Unchanged. The Note, as amended by this Amendment remains and continues in full force and effect, constitutes legal, valid, and binding obligations of each of the parties, and is in all respects agreed to, ratified, and confirmed. Any reference to the Note after the date of this Amendment is deemed to be a reference to the Note as amended by this Amendment. If there is a conflict between the terms of this Amendment and the Note, the terms of this Amendment shall control. No forbearance or waiver may be implied by this Amendment. Except as expressly set forth herein, the execution, delivery, and performance of this Amendment shall not operate as a waiver of, or as an amendment to, any right, power, or remedy of Lender under the Note, as in effect prior to the date hereof. For the avoidance of doubt, this Amendment shall be subject to the governing law, venue, and Arbitration Provisions, as set forth in the Note.

9. No Reliance. Borrower acknowledges and agrees that neither Lender nor any of its officers, directors, members, managers, equity holders, representatives or agents has made any representations or warranties to Borrower or any of its agents, representatives, officers, directors, or employees except as expressly set forth in this Amendment and the Transaction Documents and, in making its decision to enter into the transactions contemplated by this Amendment, Borrower is not relying on any representation, warranty, covenant or promise of Lender or its officers, directors, members, managers, equity holders, agents or representatives other than as set forth in this Amendment.

10. Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic signature (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

11. Further Assurances. Each party shall do and perform or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Amendment and the consummation of the transactions contemplated hereby.

[Remainder of page intentionally left blank; signature page follows]

IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date set forth above.

[Signature Page to Amendment to Secured Promissory Note]

Exhibit 99.1

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

LITTLETON, Colo., June 5, 2026 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that it has entered into a binding agreement with its senior, secured lender, Streeterville Capital, LLC (Streeterville) to exchange up to $4.5 million of its outstanding debt into a combination of perpetual, nonconvertible preferred stock and shares of common stock of the Company.

In addition, the agreement includes commitments from Streeterville to suspend any calls for repayments of its debt and any sales of Company securities for 90 and 60 days, respectively, from the date the debt-to-equity exchange becomes effective.

In June 2025, Vivos completed the acquisition of the operating assets of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada, marking the Company’s first major acquisition of a sleep testing center and associated medical sleep practice. The transaction, supported by debt financing from Streeterville and an equity investment from an affiliate of existing Vivos investor, New Seneca Partners, transformed the Company’s business model and its revenue and earnings potential.

The debt-to-equity exchange will be supported by, and is contingent on the completion of one or more qualifying equity financings on terms acceptable to the Company. There can be no assurance that any such financing will be completed, that the conditions to Streeterville’s exchange will be satisfied, or that any debt will ultimately be exchanged as contemplated.

The conversion of Streeterville’s debt into preferred and common stock, combined with the contemplated equity raise, is intended to improve the Company’s stockholders’ equity and advance its stockholders’ equity remediation plan to comply with Nasdaq’s listing standards. The transactions would, if consummated, also lower the Company’s debt service obligations, including suspending them for 90 days, which is expected to assist the Company’s cash flows and support liquidity.

This press release is being issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any securities offering, if undertaken, will be made only pursuant to applicable securities laws and definitive offering documents.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.

OSA affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA.

Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, and statements of the Company’s management and third parties (including Seneca) made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “aim,” “goal” and derivations of such words and similar expressions about the future are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual benefits of the debt restructuring, potential equity raise, the Company’s new model described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to raise the required new equity timely or in sufficient amounts, which would cause the commitment debt-to-equity exchange to become null and void; (ii) the risk that Vivos may be unable benefit fully or at all from the transactions discussed herein, even if they are consummated, (iii) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (iv) the risk that some patients may not achieve the desired results from using Vivos products, (v) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (vi) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (vii) market and other conditions, and (viii) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge at https://vivos.com/investors/sec-filings/. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Vivos Investor Relations and Media Contact:

Jennifer Hauser

Investor Relations Contact

[email protected]